Statins and Inflammation in Cardiovascular Disease
- 1 February 2018
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 23 (46) , 7027-7039
Abstract
Background: Chronic inflammation and immune system activation underlie a variety of seemingly unrelated cardiac conditions including not only atherosclerosis and the subsequent coronary artery disease but also peripheral artery disease, hypertension with target organ damage and heart failure. The beneficial effects of HMG-CoA reductase inhibitors or statins are mainly attributed to their ability to inhibit hepatic cholesterol biosynthesis. Beyond their lipid lowering activity, ample evidence exists in support of their potent anti-inflammatory properties which initiate from the inhibition of GTPase isoprenylation, activating a cataract of secondary pathways and extend to the inhibition and blocking of immune cell activation and interaction. Objective: To summarize the anti-inflammatory mechanisms of statins in clinical and experimental settings in cardiovascular disease. Methods: A systematic search of PubMed and the Cochrane Database was conducted in order to identify the majority of trials, studies, current guidelines and novel articles related to the subject. Results: In vitro, statins have immuno-modulatory and anti-inflammatory effects, and they can exert antiatherosclerotic effects independently of their hypolipidemic actions. In addition, positive results have emerged from mechanistic and experimental studies on the active role of HMG-CoA reductase inhibitors in HF. By extrapolating those data in clinical setting, we further understand how HMG-CoA reductase inhibitors can beneficially affect not only systolic but also diastolic HF. Conclusion: In this review article, we present the basic pathophysiologic data supporting the anti-inflammatory actions of statins in clinical and experimental settings and we link these mechanisms with confirmatory clinical data on the potent non lipid lowering effects of HMG-CoA reductase inhibitors.Keywords
This publication has 107 references indexed in Scilit:
- Inflammation is associated with a reduced number of pro-angiogenic Tie-2 monocytes and endothelial progenitor cells in patients with critical limb ischemiaAngiogenesis, 2015
- Microcalcifications Increase Coronary Vulnerable Plaque Rupture Potential: A Patient-Based Micro-CT Fluid–Structure Interaction StudyAnnals of Biomedical Engineering, 2012
- Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shockClinical Research in Cardiology, 2012
- Inflammatory Cytokines Imbalance in the Very Early Phase of Acute Coronary Syndrome: Correlations with Angiographic Findings and In-Hospital EventsInflammation, 2010
- Statin Therapy in Patients with Diastolic Heart FailureClinical Cardiology, 2010
- Effect of Statins, Angiotensin-Converting Enzyme Inhibitors, and Beta Blockers on Survival in Patients ≥65 Years of Age With Heart Failure and Preserved Left Ventricular Systolic FunctionThe American Journal of Cardiology, 2008
- Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: A prospective randomized controlled studyAmerican Heart Journal, 2007
- Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarctionThe American Journal of Cardiology, 2005
- Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemiaThe American Journal of Cardiology, 2004
- Beneficial effects of statins in patients with non-ischemic heart failureClinical Research in Cardiology, 2004